Gilead Sciences, Inc.'s Stock Analysis

Gilead Sciences Announces Merger Agreement with Arcellx, Inc.

Gilead Sciences, Inc. has entered into a Merger Agreement with Arcellx, Inc., under which Gilead's subsidiary will commence a tender offer to acquire all outstanding shares of Arcellx for $115.00 per share in cash, along with a contingent value right (CVR) that may provide an additional $5.00 per share upon achieving certain sales milestones of Arcellx's product. The tender offer will remain open for at least 20 business days and is subject to customary conditions, including the tender of a majority of shares and regulatory approvals.

Additionally, Gilead has secured support agreements from key stakeholders of Arcellx, representing approximately 10.3% of outstanding shares, committing to tender their shares and support the merger. The agreement includes a termination fee of $260 million payable to Gilead if Arcellx accepts a superior offer. The transaction is contingent upon various customary conditions, including regulatory approvals and the absence of legal prohibitions against the merger.

Feb 23, 2026 06:46:27

Gilead Sciences Reports 2025 Financial Results and Product Sales

Gilead Sciences reported total revenues of $29.4 billion for the full year 2025, an increase of 2% compared to 2024. Product sales, excluding Veklury, rose 4% to $28.0 billion, primarily driven by higher sales of HIV and Liver Disease products. The company noted a diluted earnings per share (EPS) of $6.78 for the full year, up from $0.38 in 2024, due to lower research and development expenses, higher revenues, and reduced selling, general, and administrative costs. The company also generated $3.3 billion in operating cash flow during the fourth quarter of 2025 and had $10.6 billion in cash and equivalents at year-end.

For the fourth quarter of 2025, Gilead's total revenues increased by 5% to $7.9 billion, driven by higher sales of HIV and Liver Disease products, although Veklury sales decreased significantly. The company reported a diluted EPS of $1.74 for the quarter, up from $1.42 in the same period in 2024. Notable product sales included Biktarvy, which increased by 5% to $4.0 billion, and Descovy, which saw a 33% increase to $819 million. The company also declared a quarterly dividend of $0.82 per share, payable on March 30, 2026, indicating ongoing shareholder returns.

Feb 10, 2026 16:02:13

Gilead Sciences Announces Departure of General Counsel Deborah Telman

Gilead Sciences, Inc. announced that Deborah H. Telman will leave her position as Executive Vice President, Corporate Affairs and General Counsel effective December 5, 2025. Her employment with the company will officially end later in December.

This leadership change may impact the company's corporate governance and legal strategies. Investors may want to monitor how this transition affects Gilead's operations and overall business direction.

Nov 19, 2025 08:30:34

Gilead Sciences Reports Q3 2025 Financial Results and Updates

Gilead Sciences announced its financial results for the third quarter of 2025, reporting total revenues of $7.8 billion, a 3% increase from the same period in 2024. Product sales, excluding Veklury, rose by 4% to $7.1 billion, driven by higher sales of HIV products and Livdelzi, while overall product sales saw a decrease of 2%. Diluted earnings per share increased to $2.43 compared to $1.00 in the prior year, primarily due to the absence of a significant prior year impairment charge and increased other revenues.

Key product sales included Biktarvy, which grew 6% to $3.7 billion, and Descovy, which saw a 20% increase to $701 million. However, Veklury sales dropped 60% to $277 million, reflecting lower COVID-19 hospitalization rates. Gilead also reported a cash position of $9.4 billion as of September 30, 2025, and generated $4.1 billion in operating cash flow during the quarter. The company declared a quarterly dividend of $0.79 per share, payable on December 30, 2025, and announced plans for significant investments in U.S. manufacturing and development.

Oct 30, 2025 16:04:07

Gilead Settles Patent Disputes, Delaying Generic Biktarvy Entry

Gilead Sciences has reached settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. to resolve patent litigations concerning Biktarvy, a medication used to treat HIV. These agreements prevent the entry of generic versions of Biktarvy in the United States before April 1, 2036, securing the company's market exclusivity for its product containing bictegravir, emtricitabine, and tenofovir alafenamide.

The settlements are subject to standard acceleration provisions. This development may impact Gilead's financial performance and market position, as the agreements help maintain the company's revenue stream from Biktarvy by delaying competition from generic manufacturers.

Oct 06, 2025 08:17:11

Gilead Sciences Appoints New Senior Vice President of Controllership

Gilead Sciences has appointed Erin Burkhart as Senior Vice President, Controllership, and principal accounting officer, effective September 22, 2025. Burkhart, who is 46 years old, has been with BioMarin Pharmaceutical Inc. as Group Vice President and Chief Accounting Officer since May 2022 and has held various accounting and finance roles at Eli Lilly and Company from 2014 to 2022.

Burkhart will succeed Diane E. Wilfong, who is stepping down from her role as interim Controller and principal accounting officer on the same date. Burkhart is a licensed certified public accountant and holds a Bachelor of Science in Accounting from Butler University.

Aug 14, 2025 16:08:22

Gilead Sciences Reports Second Quarter 2025 Financial Results

Gilead Sciences, Inc. announced its financial results for the second quarter of 2025, reporting total revenue of $7.1 billion, a 2% increase from the same period in 2024. Product sales excluding Veklury rose 4% to $6.9 billion, primarily driven by increased sales in HIV treatments, including Biktarvy and Descovy. The diluted earnings per share increased to $1.56 compared to $1.29 in the previous year, while non-GAAP diluted EPS remained flat at $2.01. As of June 30, 2025, Gilead held $7.1 billion in cash and equivalents, down from $10.0 billion at the end of 2024. The company generated $827 million in operating cash flow during the quarter and paid dividends of $994 million.

In addition to its financial performance, Gilead highlighted significant developments, including the FDA approval of Yeztugo, the first twice-yearly HIV prevention option. The company reported a strategic partnership with the Global Fund to enhance access to HIV prevention in low-income countries. Gilead's total product sales for HIV increased by 7% to $5.1 billion, with Biktarvy sales rising by 9%. However, sales from Veklury decreased by 44% due to lower COVID-19 hospitalization rates. Gilead also announced a new $6 billion stock repurchase program and declared a quarterly dividend of $0.79 per share, payable on September 29, 2025.

Aug 07, 2025 16:26:51

Gilead Sciences Updates Bylaws Affecting Director Nominations

On July 30, 2025, Gilead Sciences, Inc. approved an amendment and restatement of its bylaws, which includes changes to the nomination process for directors and proposal submissions by stockholders. The amendments clarify the disclosure requirements for proposing stockholders and nominees, restrict the number of nominees to the number of directors to be elected, and require compliance with specific regulations under the Securities Exchange Act. Additionally, the bylaw changes reserve the white proxy card for the Company's exclusive use and update provisions related to stockholder meetings and voting rights.

The revised bylaws also introduce provisions for emergency conditions and clarify the procedures for Board meetings and filling vacancies. These changes aim to modernize and enhance the governance framework of Gilead Sciences, aligning the bylaws with recent amendments to Delaware law and ensuring a clearer process for stockholder engagement at meetings.

Aug 04, 2025 16:07:16

Gilead Sciences Reports Q1 2025 Financial Results and Updates

Gilead Sciences, Inc. announced its financial results for the first quarter of 2025, reporting total revenues of $6.7 billion, which remained flat compared to the same period in 2024. Product sales excluding Veklury increased by 4% year-over-year to $6.3 billion, driven primarily by a 7% increase in Biktarvy sales, which reached $3.1 billion. The company reported a diluted earnings per share of $1.04, a significant improvement from a loss of $3.34 in the same quarter last year, largely due to the absence of prior year charges related to acquisitions. Gilead also generated $1.8 billion in operating cash flow and paid dividends totaling $1.0 billion during the quarter.

Key updates included the acceptance of New Drug Application submissions for lenacapavir for HIV prevention, with a PDUFA date set for June 19, 2025. Additionally, Gilead announced positive Phase 3 trial results for Trodelvy in combination with pembrolizumab for breast cancer treatment. The company declared a quarterly dividend of $0.79 per share, payable on June 27, 2025. As of March 31, 2025, Gilead had $7.9 billion in cash and cash equivalents, down from $10.0 billion at the end of 2024.

Apr 24, 2025 16:03:59

Gilead Reports $28.8 Billion Revenue for Full Year 2024

Gilead Sciences reported a total revenue of $28.8 billion for the full year 2024, marking a 6% increase from the previous year. Notable growth was seen in product sales, particularly in HIV and Oncology, with Biktarvy sales rising 13% to $13.4 billion. The company also reported a strong cash position of $10 billion at year-end and generated $3 billion in operating cash flow during the fourth quarter. Additionally, the product gross margin improved to 78.2% for the full year, reflecting operational efficiencies.

Conversely, Gilead's diluted earnings per share (EPS) decreased significantly to $0.38 for the full year 2024, down from $4.50 in 2023, primarily due to a substantial impairment charge related to acquired research and development projects. The sales of Veklury, which had previously contributed significantly to revenue, fell by 53% in the fourth quarter and 18% for the full year, attributed to decreased COVID-19 hospitalizations. Furthermore, research and development expenses increased, reflecting ongoing investments and integration costs from acquisitions.

Feb 11, 2025 16:04:28